Congress should limit how much public and private insurers pay for drugs that get accelerated FDA approvals until drug companies prove those drugs work, the Institute for Clinical and Economic Review says, and ICER suggests policies for doing so. Those recommendations include mandating rebates, paying only production costs, creating a single price negotiator and payer for accelerated approval drugs and mandating outcomes-based contracts. Although ICER wrote the recommendations before Aduhelm’s approval, the Alzheimer’s drug increases the importance of the recommendations...